Anemia Market Growth Fueled by FDA Approvals, Improved Screening, and Expanding Healthcare Infrastructure | DelveInsight

The anemia market is projected to experience significant growth across the seven major markets (7MM). This growth is driven by several factors, including increased disease awareness, improved screening practices, and expanding healthcare infrastructure dedicated to managing anemia. Key companies such as GSK, MegaPro Biomedical, Agios Pharmaceuticals, and Nemysis are leading the charge in innovation within this landscape.
DelveInsight's latest report, "Anemia - Market Insight, Epidemiology and Market Forecast - 2032 [https://www.delveinsight.com/report-store/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]," combines robust epidemiological data with insights into anemia market trends, competitive landscape analysis, and assessments of the patient journey. The report forecasts that the market for anemia in the 7MM, which include the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, is expected to expand positively with a decent CAGR by 2032. This expansion is primarily attributed to increased disease awareness, enhanced screening practices, and improved healthcare infrastructure dedicated to anemia management.

Download the Anemia market report to understand which factors are driving the iron deficiency anemia treatment market @ Anemia Therapeutic Market Trends [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Anemia presents through symptoms such as fatigue, weakness, dizziness, headaches, pale skin, rapid heartbeat, and shortness of breath. Nutritional deficiencies, particularly iron deficiency, are the most common causes, but folate, vitamin B12, and A deficiencies also contribute significantly. Other causes include hemoglobinopathies and infectious diseases like malaria, tuberculosis, HIV, and parasitic infections.

According to DelveInsight's report, anemia remains a significant global health concern, particularly affecting women of reproductive age. The report estimates that approximately 43% of children, 38% of pregnant women, and 29% of non-pregnant women are affected by anemia. Additionally, around 30% of all women of reproductive age have anemia, indicating that iron deficiency anemia predominantly impacts women compared to men and is more prevalent during pregnancy. The study also shows a decline in dietary iron intake of about 6.6% in males and 9.5% in females in the U.S. between 1999 and 2018.

Gain valuable insights into Anemia prevalence and patient demographics across the 7MM @ Anemia Epidemiology Analysis [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Current treatment protocols depend on the underlying causes of anemia. For iron-deficiency anemia, treatment typically involves iron supplements and dietary adjustments. Anemia due to vitamin deficiencies requires B12 or folate supplementation, while anemia related to chronic disease often necessitates erythropoiesis-stimulating agents. Diagnosis is primarily based on blood tests that measure hemoglobin levels, hematocrit, and red blood cell counts.

In the US, several medications are approved to treat anemia, including iron supplements like ferrous sulfate and iron dextran (INFeD), as well as erythropoiesis-stimulating agents (ESAs) like epoetin alfa (EPOGEN, PROCRIT) and darbepoetin alfa (ARANESP). Notably, in February 2023, JESDUVROQ (GSK) became the first oral treatment approved for anemia caused by chronic kidney disease in adults.

DelveInsight's analysis indicates that the therapeutic landscape for anemia is undergoing significant innovation, with several promising candidates in the development pipeline. Drugs such as IHAT-02/IDAX (Nemysis), AG-946 (Agios Pharmaceuticals) and MPB-1514/ IOP Injection (MegaPro Biomedical), among others are expected to enter the market during the forecast period, potentially impacting the trajectory of the anemia therapeutic market.

Recently, AG-946 (Agios Pharmaceuticals), an oral pyruvate kinase activator, demonstrated promising results in improving anemia during its phase II study.

The emergence of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) signifies a paradigm shift in treatment approaches. These oral medications offer potential advantages over traditional injectable therapies, including more consistent hemoglobin levels, improved iron utilization, and enhanced patient compliance.

Stay ahead with the latest breakthroughs, FDA approvals, and eco-friendly innovations shaping the future of the iron deficiency anemia treatment landscape. Visit Anemia Recent Developments [https://www.delveinsight.com/sample-request/anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

In conclusion, the anemia treatment market is positioned for significant growth, driven by innovative therapeutic approaches and greater awareness of this widespread condition. Oral alternatives to injectable therapies are transforming patient care, particularly for individuals with chronic kidney disease and rare blood disorders. As research advances and new therapies receive approval, patients with iron deficiency anemia, transfusion-dependent anemia, and other forms of this condition can anticipate improved outcomes and quality of life.

Table of Contents

1.

Key Insights

2.

Executive Summary of Anemia

3.

Anemia Competitive Intelligence Analysis

4.

Anemia: Market Overview at a Glance

5.

Anemia: Disease Background and Overview

6.

Patient Journey

7.

Anemia Epidemiology and Patient Population

8.

Treatment Algorithm, Current Treatment, and Medical Practices

9.

Anemia Unmet Needs

10.

Key Endpoints of Anemia Treatment

11.

Anemia Marketed Products

12.

Anemia Emerging Therapies

13.

Anemia: Seven Major Market Analysis

14.

Attribute analysis

15.

7MM: Market Outlook

16.

Access and Reimbursement Overview of Anemia

17.

KOL Views

18.

Anemia Market Drivers

19.

Anemia Market Barriers

20.

Appendix

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

Related Reports

Iron Deficiency Anemia Pipeline Insight [https://www.delveinsight.com/report-store/iron-deficiency-anemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Iron Deficiency Anemia Pipeline Insight provides comprehensive insights about the Iron Deficiency Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Iron Deficiency Anemia manufacturers, including Keros Therapeutics Inc(NASDAQ: KROS), Rockwell Medical Inc (NASDQA: RMTI), Disc Medicine Inc (NASDAQ: IRON), Pharmacosmos AS, Shield Therapeutics Plc, Akebia Therapeutics Inc (NASDAQ: AKBA), Entrinsic Bioscience Inc, Iron4u Aps, Jiangsu Aosaikang Pharmaceutical Co Ltd, and Nemysis Ltd, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anemia-market-growth-fueled-by-fda-approvals-improved-screening-and-expanding-healthcare-infrastructure-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.